Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialByeong-Ho Park, David H. Kirn, Jae‐Seok Kim et al.|The Lancet Oncology|2008Cited by 522
Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia VirusDavid H. Kirn, Steve H. Thorne|PLoS Medicine|2007Cited by 202
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963Steve H. Thorne, David H. Kirn|Journal of Clinical Investigation|2007Cited by 198
A Phase I Trial of Ad.hIFN-β Gene Therapy for GliomaE. Antonio Chiocca, David H. Kirn, Katie Smith et al.|Molecular Therapy|2008Cited by 118